All about the counterfeit ‘Abhayrab’ rabies vaccine batch under investigation
A batch of the widely used human rabies vaccine Abhayrab has been flagged as substandard and is under investigation for being potentially spurious, after it failed a potency test
The flagged vials, bearing a specific batch number, were seized from an unlicensed premises during an enforcement action, and were found to differ from genuine reference samples in packaging, labelling, QR-code verification, cap colour, and licence details
This is the second time in under two years that counterfeit doses of the same vaccine brand have been reported in the market
Regulatory scrutiny of the batch highlights the narrow margin for error in rabies prevention, since a genuine vaccine administered promptly prevents a fatal disease, while a counterfeit product can create a false sense of protection
Rabies Post-Exposure Prophylaxis (PEP) — WHO Bite Categories
The World Health Organization classifies animal bite exposures into three categories that determine the treatment protocol: touching or feeding an animal (Category I, no PEP needed), minor scratches or nibbles without bleeding (Category II, requires vaccine only), and transdermal bites, scratches with bleeding, or licks on broken skin/mucous membranes (Category III, requires vaccine plus rabies immunoglobulin). A genuine, potent vaccine is essential at every step of this protocol, since rabies is nearly always fatal once symptoms appear.
Key Details
- Category III exposures require both anti-rabies vaccine and rabies immunoglobulin (RIG) — vaccine alone is considered insufficient
- India's National Centre for Disease Control (NCDC) issued National Guidelines on Rabies Prophylaxis in 2019, standardising bite categorisation, vaccination regimens, and route of administration
- Recommended intramuscular regimens include the 5-dose Essen regimen and the 4-dose Zagreb regimen; the Thai Red Cross regimen is used for intradermal administration
- Rabies has a case fatality rate of nearly 100% once clinical symptoms develop, making pre-symptomatic PEP the only effective intervention
A counterfeit or substandard vaccine batch undermines PEP at exactly the stage where treatment is time-critical and irreversible if it fails — a patient administered a spurious dose may believe they are protected when they are not.
Regulatory Framework — Drugs and Cosmetics Act, 1940 and "Spurious" Drugs
The Drugs and Cosmetics Act, 1940, and its 1945 Rules, govern the manufacture, sale, and quality of drugs in India, including vaccines. Section 17B of the Act defines a "spurious" drug — one manufactured under a false name, imitating another drug in a deceptive manner, bearing a fictitious manufacturer's details, or substituted wholly or partly with another substance. Enforcement is carried out jointly by the Central Drugs Standard Control Organisation (CDSCO) and state drug control authorities.
The flagged Abhayrab batch is being investigated under this framework — the vaccine failed a potency test (raising an NSQ concern) while differences in packaging and licensing details raised the more serious possibility that it is spurious under Section 17B, which carries markedly higher penalties.
National Rabies Control Programme and India's Rabies Burden
India accounts for a disproportionate share of the world's human rabies deaths, driven primarily by dog bites. The National Rabies Control Programme, under the National Health Mission, aims to reduce human rabies deaths through free PEP availability at government health facilities, animal bite management training, and coordination with animal husbandry authorities for dog vaccination, working toward the global target of zero human rabies deaths by 2030.
Key Details
- India has among the highest burdens of human rabies deaths globally, with dog bites responsible for the vast majority of cases
- The National Rabies Control Programme operates as a component under the National Health Mission (NHM), Ministry of Health and Family Welfare
- The global "Zero by 30" target (zero human deaths from dog-mediated rabies by 2030) is a joint initiative of WHO, FAO, and the World Organisation for Animal Health (WOAH)
- Rabies vaccines like Abhayrab are supplied both commercially and through government immunisation programmes, meaning a compromised batch has implications beyond the private market
Because government PEP programmes rely on manufacturers such as the one whose brand was counterfeited, a spurious-batch scare threatens public confidence in a programme central to India's "Zero by 30" rabies elimination commitment.
- WHO bite exposure categories: I (no PEP), II (vaccine only), III (vaccine plus immunoglobulin)
- India's National Guidelines on Rabies Prophylaxis: issued by NCDC, 2019
- Standard intramuscular PEP regimens: 5-dose Essen, 4-dose Zagreb; intradermal: Thai Red Cross regimen
- Spurious drug offence (Section 17B, Drugs and Cosmetics Act 1940): minimum 7 years' imprisonment up to life, minimum fine ₹3 lakh or 3x value of drugs seized
- This is the second reported instance of counterfeit doses of this vaccine brand in under two years
- Global elimination target: zero human deaths from dog-mediated rabies by 2030 ("Zero by 30," WHO-FAO-WOAH initiative)
- Rabies case fatality rate once symptoms appear: near 100%